Retatrutide represents the next generation of metabolic research. As a unique triple agonist targeting GLP-1, GIP, and Glucagon (GCGR) receptors, it offers a more comprehensive approach to body fat mass reduction compared to single or dual-agonist precursors. Each 30mg vial contains high-purity lyophilized powder, providing a potent tool for investigating advanced weight management and metabolic signaling pathways.